Login / Signup

Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years.

Sabine KürzelAndré-René BlaudszunLilly StahlRegina HerbstFrank KroschinskyJosef BirkmannAnnette HänelKerstin Schaefer-EckartGerhard EhningerFriedrich FiedlerMartin BornhäuserStephan FrickeMathias Hänel
Published in: Journal of cancer research and clinical oncology (2021)
7 April 2021, retrospectively registered.
Keyphrases
  • diffuse large b cell lymphoma
  • open label
  • cross sectional
  • double blind
  • placebo controlled
  • randomized controlled trial
  • monte carlo